Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027947 (neutropenia)
 17,527 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors describe the development of a clinical protocol to treat mustard gas-induced myelosuppression with granulocyte colony stimulating factor (G-CSF), a hematopoietic growth factor. Limited clinical evidence suggests a significant role for mustard gas-induced myelosuppression in the overall morbidity of mustard gas victims. Initial data from primates revealed that G-CSF could ameliorate neutropenia following nitrogen mustard exposure. Exploiting the extensive oncologic experience with G-CSF, which demonstrated its safety and absence of serious side effects the authors developed a clinical protocol for use of this drug in potential mustard gas victims in the Persian Gulf conflict.
Mil Med 1993 Jul
PMID:Granulocyte colony stimulating factor (G-CSF) for mustard-induced bone marrow suppression. 768 84

Myelokathexis is a rare from of neutropenia that is probably congenital, characterized by severe noncyclic neutropenia, recurrent infections, granulocytic hyperplasia of the bone marrow, and degenerative changes in mature neutrophils. The cause remains uncertain. A case of myelokathexis was reported in a father and two daughters, and based on this, myelokathexis was given an autosomal-dominant inheritance in Mendelian Inheritance in Man (11th edition, 1994). We present the case of a 12-month-old male with chronic neutropenia and the morphologic features of myelokathexis whose mother carries the same diagnosis, providing additional evidence in favor of dominant transmission.
Mil Med 1997 Dec
PMID:Myelokathexis in a mother and infant: a second case suggesting dominant inheritance. 943 92

We observed 71 febrile, neutropenic episodes in 25 oncohematological patients after chemotherapy during a 3-years period from 1995 to 1997. Three patients died because of infections (pneumonia with septic shock, gram-negative bacteremia and sepsis, pseudomembranous colitis and diffuse peritonitis) at the period of prolonged, deep neutropenia (absolute neutrophil count < 100/mm3). During the 71 febrile, neutropenic episodes, we observed 24 bacteremia (33.8%) and 1 fungemia (1.4%). There were 35 cases of microbiologically documented and 12 cases of clinically documented infections. In 24 patients, the origin of fever was unknown. We analyzed the characteristics of infections, microbes and their susceptibility conditions, and the efficacy of empiric antimicrobial therapy.
Mil Med 2003 May
PMID:Infections of febrile neutropenic patients in malignant hematological diseases. 1277 68

Although best known as a blistering agent, sulfur mustard (HD) can also induce neutropenia in exposed individuals, increasing their susceptibility to infection. Granulocyte colony-stimulating factor (G-CSF) and pegylated G-CSF (peg-G-CSF) have been approved by the U.S. Food and Drug Administration as hematopoietic growth factors to treat chemotherapy-induced neutropenia. The goal of this study was to determine the effectiveness of G-CSF and peg-G-CSF in ameliorating HD-induced neutropenia. African green monkeys (Chlorocebus aethiops) were challenged with HD and, at 1, 3, 5, or 7 days after exposure, G-CSF therapy (10 microg/kg per day for 21 days) was initiated. Peg-G-CSF (300 microg/kg, single treatment) was similarly tested, with treatment given at 3 days after exposure. Untreated HD-exposed animals recovered from neutropenia 28 days after exposure, whereas G-CSF- or peg-G-CSF-treated animals recovered 8 to 19 days after exposure (p < 0.05). These results indicate that G-CSF or peg-G-CSF may provide Food and Drug Administration-approved treatments that will reduce the duration of HD-induced neutropenia.
Mil Med 2006 May
PMID:Sulfur mustard-induced neutropenia: treatment with granulocyte colony-stimulating factor. 1676 98

We report on a 43-year-old patient with septic aneurysm complicated by rupture of the pelvis of the kidney due to Salmonella enteritidis that we treated successfully by empiric therapy, then targeted antibiotic therapy and late surgical intervention with iliofemoral crossover bypass grafting and aneurysm resection. The course was complicated by deep neutropenia and chronic hepatitis C infection.
Mil Med 2007 Oct
PMID:Successful treatment of a septic aneurysm due to Salmonella enteritidis complicated by the rupture of the pelvis of the kidney. 1798 76

Acquired agranulocytosis is a rare, life-threatening disorder. The few known causes/associations usually are readily identifiable (e.g., drug reaction, Felty syndrome, megaloblastosis, large granular lymphocytic leukemia, etc.). We report a novel association with mast cell disease. A 61-year-old morbidly obese man developed rheumatoid arthritis unresponsive to several medications. Agranulocytosis developed shortly after sulfasalazine was started but did not improve when the drug was soon stopped. Other symptoms across many systems developed including hives and presyncope. Marrow aspiration and biopsy showed only neutropenia. Serum tryptase was mildly elevated; urinary prostaglandin D2 was markedly elevated. Other causes were not found. Mast cell activation syndrome (MCAS) was diagnosed. Oral antihistamines, montelukast, and cromolyn were unhelpful; aspirin was initially felt contraindicated. Imatinib immediately increased neutrophils from 0% to 25% but did not help symptoms; subsequent addition of aspirin increased neutrophils further and abated symptoms. Different presentations of different MCAS patients reflect elaboration of different mediators likely consequent to different Kit mutations. Mast cells (MCs) help regulate adipocytes, and adipocytes can inhibit granulopoiesis; thus, a Kit-mutated MC clone may have directly and/or indirectly driven agranulocytosis. MCAS should be considered in otherwise idiopathic agranulocytosis presenting with comorbidities best explained by MC mediator release.
Mil Med 2012 Jan
PMID:Mast cell activation syndrome masquerading as agranulocytosis. 2233 92

Cefazolin, a first generation cephalosporin, is a rare cause of cyclical fevers, neutropenia, and thrombocytopenia following surgical prophylaxis. We present the case of an otherwise healthy 21-year-old male who sustained a 50-cm laceration to his chest and abdomen. He received emergency department prophylaxis with cefazolin and surgical repair. Subsequently, he developed cyclical fevers, neutropenia, and thrombocytopenia, all of which resolved after antibiotic discontinuation. This is the first case report in which the perioperative administration of cefazolin following trauma resulted in significant neutropenia and thrombocytopenia. Also discussed in this report are the etiology, workup, and treatment of cefazolin-induced neutropenia.
Mil Med 2012 Mar
PMID:Cefazolin-induced neutropenia and thrombocytopenia following trauma: a case report. 2247 26